January 6, 2023
Life Sciences
  • Moderna Inc. announced a $35 million licensing deal with CytomX Therapeutics for the development of certain investigational messenger RNA-based therapies. The deal offers CytomX access to Moderna’s mRNA technology, which has been used to develop COVID-19 vaccines, while Moderna would get access to CytomX’s Probody platform, used in the development of cancer therapies targeting diseased tissues. (Article here)